论文部分内容阅读
目的探讨胰激肽原酶治疗糖尿病肾病的临床疗效与安全性。方法选择糖尿病肾病患者63例,随机分为对照组30例和治疗组33例,对照组给予糖尿病饮食、口服降糖药及或胰岛素治疗,治疗组在上述治疗的基础上加用胰激肽原酶注射液,4周后分别检测两组患者的肾功能变化和24h尿蛋白定量情况。结果治疗组血肌酐、尿素氮、尿白蛋白排泄率(UAER)均显著下降(P<0.01),治疗组效果优于对照组(P<0.01),无明显不良反应发生。结论胰激肽原酶注射液治疗糖尿病肾病安全有效。
Objective To investigate the clinical efficacy and safety of pancreatic kininogenase in the treatment of diabetic nephropathy. Methods Sixty-three patients with diabetic nephropathy were randomly divided into control group (n = 30) and treatment group (n = 33). The control group was given diabetes diet, oral hypoglycemic agents and insulin therapy. The treatment group was treated with pancreatic kallikrein Enzyme injection, after 4 weeks were detected in two groups of patients with renal function changes and 24h urinary protein quantitative. Results Serum creatinine, urea nitrogen and urinary albumin excretion rate (UAER) of the treatment group were significantly decreased (P <0.01), and the treatment group was better than the control group (P <0.01), no obvious adverse reactions occurred. Conclusion pancreatic kallikrein injection for the treatment of diabetic nephropathy safe and effective.